Sandoz
506 Carnegie Center Drive, Suite 400
Princeton
New Jersey
08540
United States
Tel: 609-627-8500
Fax: 609-627-8683
Website: http://www.us.sandoz.com/
125 articles with Sandoz
-
Sandoz exclusively launches treprostinil injection, the first generic version of Remodulin®, in the US
3/25/2019
Sandoz announced the US availability of Treprostinil Injection, the first fully substitutable AP rated generic version of Remodulin®* Injection, sold by United Therapeutics Corporation, including 180 days of marketing exclusivity for the product.
-
The United Food and Commercial Workers Local 1500 (UFCW Local 1500) filed a class action lawsuit against AbbVie for allegedly using a group of patents to maintain a monopoly on its blockbuster Humira (adalimumab).
-
BioSpace Movers and Shakers: March 15
3/15/2019
Biotech and pharma companies make changes to their executive leadership teams, with moves at Sandoz, PAREXEL, FSD, Karuna, Precision Bio, and more. -
Francis’ last day with Sandoz will be March 31. Francesco Balestrieri, who is currently Region Head Europe for Sandoz, has been appointed interim CEO. He will report to Vas Narasimhan, the CEO of Novartis
-
Sandoz Inc. launches authorized generic version of buprenorphine and naloxone sublingual film
2/19/2019
Sandoz Inc., a Novartis division, announced that the authorized generic of SUBOXONE® 1 Sublingual Film by Indivior Inc.
-
Sandoz Inc. launches SYMJEPI™ (epinephrine) in the US
1/16/2019
Sandoz Inc. (Sandoz), a Novartis division, announced the US market introduction of SYMJEPI™ (epinephrine) 0.3 mg Injection for the emergency treatment of allergic reactions (Type 1), including anaphylaxis.
-
On Tuesday, Sandoz AG, Novartis’ subsidiary focused on generic drugs and biosimilars, teamed up with Tilray Canada, Ltd., a subsidiary of Tilray Inc. to increase availability of high quality medical cannabis products across the globe.
-
Sandoz Inc. and Pear Therapeutics Obtain FDA Clearance for reSET-O™ to Treat Opioid Use Disorder
12/10/2018
reSET-O™ is the first FDA-cleared Prescription Digital Therapeutic (PDT) for patients with Opioid Use Disorder
-
What’s Going on With the Biosimilar Market?
12/10/2018
Although a moderate presence in Europe, with about 25 biosimilars approved and on the market, they haven’t gained traction in the U.S. Even though at least 11 have been approved in the U.S., only about three are available, largely because of business tactics branded drug companies are using to sl... -
Sandoz and Pear Therapeutics Announce Launch of reSET® for Treatment of Patients with Substance Use Disorder
11/19/2018
reSET® is the first and only FDA-authorized prescription digital therapeutic for Substance Use Disorder (SUD)
-
Novartis has been on something of a housecleaning binge since Vasant (Vas) Narasimhan took over the chief executive officer position from Joseph Jimenez in January of this year. On October 30, Novartis indicated it planned to abandon approximately 20 percent of its research projects.
-
Sandoz Inc. Issues Voluntary Nationwide Recall of One Lot of Losartan Potassium and Hydrochlorothiazide Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient (API)
11/8/2018
Sandoz Inc. is voluntarily recalling one lot of Losartan Potassium Hydrochlorothiazide Tablets, USP 100mg/25mg to the consumer level.
-
The U.S. Food and Drug Administration (FDA) gave the green light to Hyrimoz, a biosimilar to AbbVie’s blockbuster drug Humira, five years ahead of the time it can be launched in U.S. markets.
-
Part of the Trump Administration and the U.S. Food and Drug Administration (FDA)’s strategy to push down drug prices is to develop ways to increase competition. As such, the agency launched a Drug Competition Action Plan that has several components.
-
Amidst Strong Quarterly Growth, Novartis Receives FDA Complete Response Letter for Canakinumab
10/18/2018
Buried deep in an announcement touting a 6 percent growth in net sales driven by strong revenue gains of Cosentyx, Swiss pharma giant Novartis reported it received a Complete Response Letter from the U.S. Food and Drug Administration for canakinumab as a potential treatment for cardiovascular ris... -
AbbVie’s Humira is the world’s best-selling drug that generated more than $18 billion for the Illinois-based company last year. This week though, the company will begin to see challenges to Humira in Europe from biosimilars developed by Amgen and Novartis, as well as others.
-
AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Sandoz
10/11/2018
AbbVie announced today a global resolution of all intellectual property-related litigation with Sandoz over its proposed biosimilar adalimumab product.
-
Sandoz Inc. announces US FDA approval of pediatric dose of SYMJEPI™ (epinephrine)
9/27/2018
Sandoz Inc. today announced that the US Food and Drug Administration has approved SYMJEPI™ (epinephrine) 0.15 mg Injection for the emergency treatment of allergic reactions in children.
-
Alcon, the Novartis eye care business, is leaving its longtime home of Texas for Switzerland. The company said it will move its corporate headquarters from Fort Worth to Geneva following the spinoff from Novartis.
-
Today Narasimhan and Novartis announced they were selling U.S. dermatology and generic drug assets, parts of its Sandoz division, to India’s Aurobindo Pharma for up to $1 billion. The deal includes approximately 300 products.